Brokers usually take bids until: Zerodha 4:45 PM, Groww 4:50 PM, Angel One and Upstox 5:00 PM (HNI 4:00 PM). Check the exact time with your broker or bank.
Total Issue Size
Fresh Issue + Offer For Sale
Fresh Issue (FI)
Proceeds go to the company
Offer For Sale (OFS)
Proceeds go to the existing investors
Setting up new IVF centres
Capital expenditure towards establishing new IVF centres.
Repayment of borrowings
Repayment or prepayment, in full or in part, of certain outstanding loans of the company.
Inorganic growth and general corporate purposes
Funding inorganic growth initiatives and general corporate purposes.
(₹ in Crore)
Tap a bar to highlight a metric across periods and show its values.
Gaudium IVF & Women Health Limited, incorporated in March 2015 and founded by Dr. Manika Khanna, is a fertility healthcare company that provides In Vitro Fertilization and related women's health services across India. It runs on a hub and spoke model, pairing a set of full service treatment centres with a wider network of feeder locations, and had grown to more than thirty locations, made up of about seven hubs and twenty eight spokes, partly through a strategic alliance with Infertility Experts. The company offers a comprehensive fertility and reproductive care portfolio that includes In Vitro Fertilization, Intracytoplasmic Sperm Injection, Intrauterine Insemination and ovulation induction, alongside broader gynaecological care for conditions such as PCOD, PCOS and endometriosis. Its centres are spread across cities including Delhi, Mumbai, Ludhiana, Srinagar, Patna and Bangalore, giving it a multi state footprint in a segment where demand is concentrated in larger urban centres. The business is led by its founder promoters and positions itself in the fast growing Indian fertility treatment market. Its stated growth plan centres on adding new IVF centres and strengthening its balance sheet, with the fresh capital from this offer directed largely at capital expenditure for new centres and at repaying part of its outstanding borrowings.
The company raised about Rs 49.5 crore ahead of the issue by allotting 62,65,860 equity shares to four anchor investors at Rs 79 per share. Meru Investment Fund took the largest portion at around Rs 17 crore, followed by Sanshi Fund at about Rs 12.5 crore, with Hornbill Orchid India Fund and Carnelian India Multi-Strategy Fund putting in roughly Rs 10 crore each.
Source: RHP • Analysis provided for informational purposes
Last Updated: 9 July 2026, 5:30 AM
Specialist fertility brand
The company is an IVF focused provider founded and led by an experienced fertility specialist, giving it a recognised name in its niche.
Scalable hub and spoke network
A pan India network of hubs and feeder spokes lets it extend reach and add capacity without a full centre at every location.
Broad fertility care portfolio
Services span IVF, ICSI, IUI and ovulation induction plus wider gynaecological care, covering most of a patient's treatment journey.
Growing revenue and profitability
Revenue and profit have generally trended up over recent years, supported by rising treatment volumes.
Large and expanding market
It operates in the Indian fertility treatment market, which is projected to grow at a healthy pace.
High contingent liabilities
Contingent liabilities are large relative to net worth, which could strain finances if they crystallise.
Clinical and legal exposure
As a healthcare provider it faces operational and legal risks inherent in delivering medical services.
Reliance on skilled staff
High attrition and a dependence on specialist doctors and embryologists could disrupt operations.
Gaudium IVF & Women Health Limited
B1/51, Janakpuri East, (Near Janakpuri East Metro Station), New Delhi 110058, India
View on Maps →No financial information whatsoever published anywhere, within this website, should be considered as an advice to buy or sell securities or invest in IPOs, or as a guide to doing so in any way whatsoever. All matter published here is purely for educational and information purposes only and under no circumstances should be used for making investment decisions.
We are not a SEBI Registered analyst. Readers must consult a qualified financial advisor prior to making any actual investment decisions, based on information published on this website. The information on this website is based on information available as on date coupled with market perceptions.
You agree with the terms and conditions to use this website.
Grey-market disclaimer. GMP shown here is grey-market news only. We do not trade or deal in the grey market or subject-to rates, nor do we recommend trading in the grey market.
Not investment advice. IPO Nex is an information tool, not investment advice. We do not recommend buying or selling any securities. Always do your own research before applying to any IPO.
IPO Nex does not guarantee any listing gain or return. IPO investments are subject to market risks.
All times are IST.
© 2026 IPO Nex by Niota. All rights reserved.
Promoter dependence
The business leans heavily on its promoters for leadership and brand value.
Cash flow and borrowing pressure
Past negative cash flows and rising borrowings could limit financial flexibility.